secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269470
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M
--------------------------------------------------------------------------------

- 89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.
- Introduced trispecific molecules APVO451 and APVO452 for solid tumors, expanding CD3 T-cell engager portfolio to five candidates.
- Raised $18.7M net in Q3 and additional $4.1M in October; proforma cash $25.2M extends runway into 4Q26.
- Q3 net loss $7.5M ($2.23 per share) vs $5.1M ($357.86 per share) in Q3 2024; R&D spend $4.0M, G&A $3.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/0001193125-25-269470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/apvo-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer